Fusion Antibodies (FAB) Competitors GBX 14 0.00 (0.00%) As of 08/22/2025 11:50 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock FAB vs. REDX, ETX, SBTX, COS, C4XD, FUM, DDDD, TRX, SAR, and ARECShould you be buying Fusion Antibodies stock or one of its competitors? The main competitors of Fusion Antibodies include Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), Futura Medical (FUM), 4D pharma (DDDD), Tissue Regenix Group (TRX), Sareum (SAR), and Arecor Therapeutics (AREC). These companies are all part of the "biotechnology" industry. Fusion Antibodies vs. Its Competitors Redx Pharma e-therapeutics SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery Futura Medical 4D pharma Tissue Regenix Group Sareum Arecor Therapeutics Redx Pharma (LON:REDX) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Is REDX or FAB more profitable? Redx Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. Fusion Antibodies' return on equity of -137.11% beat Redx Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Redx PharmaN/A -180.80% -43.95% Fusion Antibodies -195.95%-137.11%-63.78% Which has stronger valuation & earnings, REDX or FAB? Fusion Antibodies has lower revenue, but higher earnings than Redx Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedx Pharma£4.20M0.00-£33.16M-£0.10N/AFusion Antibodies£2.09M6.29-£4.10M-£4.45-3.15 Does the media refer more to REDX or FAB? In the previous week, Redx Pharma's average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score. Company Overall Sentiment Redx Pharma Neutral Fusion Antibodies Neutral Which has more volatility and risk, REDX or FAB? Redx Pharma has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500. Comparatively, Fusion Antibodies has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Do institutionals and insiders hold more shares of REDX or FAB? 72.7% of Redx Pharma shares are owned by institutional investors. Comparatively, 21.0% of Fusion Antibodies shares are owned by institutional investors. 18.4% of Redx Pharma shares are owned by company insiders. Comparatively, 11.4% of Fusion Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryRedx Pharma beats Fusion Antibodies on 6 of the 10 factors compared between the two stocks. Get Fusion Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FAB vs. The Competition Export to ExcelMetricFusion AntibodiesBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£13.17M£137.09M£5.76B£3.22BDividend YieldN/A3.74%4.41%5.04%P/E Ratio-3.153.8731.10164.64Price / Sales6.294,057.33433.22310,107.82Price / Cash9.0213.1937.7327.93Price / Book3.9846.309.535.90Net Income-£4.10M-£90.99M£3.26B£5.89B7 Day Performance-20.90%0.41%2.10%48.38%1 Month Performance55.56%3.50%2.81%55.09%1 Year Performance314.20%205.45%30.56%135.38% Fusion Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FABFusion AntibodiesN/AGBX 14flatN/A+334.5%£13.17M£2.09M-3.1548Gap DownREDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101Gap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295K-450.0035High Trading VolumeSBTXSkinBioTherapeuticsN/AGBX 14.32+2.3%N/A+19.1%£32.70M£1.56M-8.8011COSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeFUMFutura MedicalN/AGBX 9.70-1.6%N/A-73.9%£30.23M£8.68M-8.0012Gap DownDDDD4D pharmaN/AN/AN/AN/A£30.05M£718K-1.08106TRXTissue Regenix GroupN/AGBX 30+3.4%N/A-51.9%£27.05M£31.98M-30.97120SARSareumN/AGBX 19.90+3.4%N/A-25.5%£24.86MN/A-4.713,211Gap DownARECArecor TherapeuticsN/AGBX 63.11-0.6%N/A-28.6%£23.83M£6.04M-2.2310Gap Up Related Companies and Tools Related Companies Redx Pharma Alternatives e-therapeutics Alternatives SkinBioTherapeutics Alternatives Collagen Solutions plc (COS.L) Alternatives C4X Discovery Alternatives Futura Medical Alternatives 4D pharma Alternatives Tissue Regenix Group Alternatives Sareum Alternatives Arecor Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:FAB) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access